<DOC>
	<DOCNO>NCT01462214</DOCNO>
	<brief_summary>In present phase 1-2 study investigator aim determine whether depletion Tregs use metronomic cyclophosphamide enhance antitumor efficacy everolimus patient mRCC amenable progressive VEGF-receptor tyrosine kinase inhibitor contain treatment regimen . In phase 1 part study investigator determine optimal CD4+CD25+ regulatory T cell-depleting dose schedule metronomic oral cyclophosphamide give combination fix dose ( 10 mg daily ) everolimus . In phase 2 part study investigator subsequently evaluate whether number patient cancer progression free 4 month increase 50 % 70 % add metronomic cyclophosphamide ( dose schedule determine phase 1 part ) everolimus . In addition efficacy , investigator evaluate treatment toxicity determine whether combination strategy feasible safe .</brief_summary>
	<brief_title>Study Everolimus Low-dose Cyclophosphamide Patients With Metastatic Renal Cell Cancer</brief_title>
	<detailed_description>This phase I/II , national multi-center study different dos schedule low-dose oral cyclophosphamide combination fix dose everolimus patient mRCC amenable progressive VEGF-receptor tyrosine kinase inhibitor contain treatment regimen . Phase I part : Patients enrol cohort 5 per dose level . The first 5 patient enrol assign dose level 0 order ass immune angiogenic effect cause everolimus monotherapy . The second 5 patient enrol assign dose level 1 . If ≤1 dose-limiting toxicity ( DLTs ) experience first 5 patient cohort first 28 day first study treatment , patient enter next dose level . Entry patient expansion cohort occur least 28 day last patient escalation phase receive his/her first study treatment . At final dose level recommend phase II study minimum 10 patient treat . Phase II part : In phase 2 part study 56 patient treat dose level select base capacity selectively deplete circulate Treg level phase 1 part study . Based data patient mRCC treat everolimus monotherapy previous treatment sunitinib ± sorafenib , investigator aim increase number patient alive cancer progression free 4 month 50 % 70 % add metronomic cyclophosphamide . In addition , investigator consider increase meaningful long combination treatment cause combination treatment related toxicity ≥ grade 3 ≥ 30 % patient .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients histologically cytologically confirm clearcell mRCC progressive disease amenable progressive within 6 month stop treatment VEGF receptor tyrosine kinase inhibitor ( sunitinib ( pazopanib ) ± sorafenib ) . Prior therapy cytokine ( i.e . IL2 , interferon ) and/or VEGFligand inhibitor ( i.e . bevacizumab ) permit . Patients brain metastasis eligible stable least two month postradiation therapy surgery . Aged 18 year old . No current malignant disease , except basal cell carcinoma skin . WHO performance status 02 . Life expectancy least 12 week . Adequate hematologic function : ANC ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , Hb ≥ 6.0 mmol/L . Adequate hepatic function : serum bilirubin ≤ 1.5 x ULN , ALT AST ≤ 2.5 x ULN ( ≤ 5 time ULN liver metastasis present ) . Adequate renal function : calculated creatinine clearance ≥ 50 ml/min . Measurable evaluable disease define RECIST 1.1 . Patients reproductive potential must use effective contraception . Female patient must negative pregnancy test . Signed informed consent . Able receive oral medication . Patients currently receive chemotherapy , immunotherapy , radiotherapy receive ≤ 4 week prior visit 1 . The washout period sunitinib sorafenib least 2 week first dose study medication . Known human immunodeficiency virus ( HIV ) major immunodeficiency . Immunosuppressive agent within 3 week study entry , except low dose corticosteroid give disorder rheumatoid arthritis , asthma , adrenal insufficiency . Topical inhale corticosteroid permit . Patients active bleed diathesis oral antivitamin K medication . Patients untreated CNS metastases clinical symptom receive treatment CNS metastases within 2 month study entry . Patients treat CNS metastasis , neurologically stable corticosteroid 2 month prior study entry eligible enter study . Active infection serious intercurrent illness , except asymptomatic bacteriuria . Presence unstable angina , recent myocardial infarction ( within previous 6 month ) , use ongoing maintenance therapy lifethreatening ventricular arrhythmia . Macroscopic hematuria Prior therapy mTOR inhibitor . 10 . Known hypersensitivity everolimus rapamycins ( sirolimus/temsirolimus ) excipients . Pregnant nursing woman , woman childbearing potential utilizing effective contraceptive method . A woman childbearing potential define female biologically capable become pregnant . Men partner childbearing potential use effective method contraception . ( Use effective contraceptive must continue 3 month last dose everolimus ) . Presence significant central nervous system psychiatric disorder ( ) would hamper patient 's compliance . Uncontrolled diabetes define fast serum glucose &gt; 2 ULN , severely impaired lung function . Cirrhosis/chronic active hepatitis/chronic persistent hepatitis , history HCV infection ( hepatitis screen indication see section 3.3 ) . Drug alcohol abuse . Any major illness , investigator 's judgment , substantially increase risk associate subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>